Investigating the potential of next-generation sequencing in identifying Alzheimer’s biomarkers
### Investigating the Potential of Next-Generation Sequencing in Identifying Alzheimer’s Biomarkers
Alzheimer’s disease is a complex condition that affects millions of people worldwide. It is characterized by the buildup of proteins in the brain, leading to memory loss and cognitive decline. Researchers are working hard to find new ways to diagnose and treat Alzheimer’s, and one promising area of research is the use of next-generation sequencing (NGS) to identify biomarkers.
#### What Are Biomarkers?
Biomarkers are substances in the body that can be measured to indicate the presence of a disease. In the case of Alzheimer’s, biomarkers could help doctors diagnose the disease earlier and monitor its progression. Traditional biomarkers often involve analyzing cerebrospinal fluid (CSF) or brain tissue, which can be invasive and difficult to obtain.
#### How Does Next-Generation Sequencing Work?
NGS is a powerful tool that allows researchers to read the genetic code of an organism with unprecedented speed and accuracy. By analyzing the genetic material from blood or other tissues, scientists can identify specific patterns or changes that are associated with Alzheimer’s disease.
#### Recent Studies on Alzheimer’s Biomarkers
Several recent studies have shown the potential of NGS in identifying Alzheimer’s biomarkers. For example, a study published in 2024 used high-throughput RNA sequencing to analyze brain tissue from healthy and diseased individuals. The researchers found that certain genes and pathways were downregulated in people with Alzheimer’s, which could serve as potential biomarkers[3].
Another study used machine learning techniques to analyze blood gene expression profiles from participants in the Alzheimer’s Disease Neuroimaging Initiative (ADNI). The researchers were able to identify new genetic biomarkers associated with Alzheimer’s disease and achieved high accuracy in diagnosing the stages of the disease[2].
#### The Role of Blood Biomarkers
Blood-based biomarkers are particularly promising because they are less invasive than CSF or brain tissue analysis. A study published in 2025 highlighted the potential of blood gene expression profiles in diagnosing Alzheimer’s disease using machine learning-based multiclassifiers. The study found that certain genes, such as MAPK14, PLG, FZD2, FXYD6, and TEP1, were associated with an increased risk of Alzheimer’s[2].
#### Future Directions
The use of NGS in identifying Alzheimer’s biomarkers is still in its early stages, but it holds great promise. Future research will focus on validating these findings and developing personalized treatment approaches. Additionally, integrating genomic data with therapeutic strategies could lead to more precise and effective treatments for Alzheimer’s disease.
In summary, next-generation sequencing is a powerful tool that is helping researchers identify new biomarkers for Alzheimer’s disease. By analyzing genetic material from blood or other tissues, scientists can uncover specific patterns associated with the disease. This research has the potential to lead to earlier diagnoses and more effective treatments, improving the lives of those affected by Alzheimer’s.
—
### References
1. **Genomic and Transcriptomic Approaches Advance the Diagnosis and Prognosis of Neurodegenerative Diseases**. (2025). MDPI.
2. **Machine Learning-Based Alzheimer’s Disease Stage Diagnosis Using Blood Gene Expression Profiles**. (2025). PubMed.
3. **Focus on Potential Gene Signatures and Drugs for Dementia**. (2025). PubMed.
